EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma

Jun-Peng Lin, Hui Lin, Hao He, Feng-Nian Zhuang, Wei-Jie Chen, Yu-Jie Chen, Peiyuan Wang, Hang Zhou, Wen-Wei Wei, Peng-Qiang Gao, Shuo-Yan Liu, Feng Wang

Frontiers in Immunology · 29.04.2026 · 17

DOI: 10.3389/fimmu.2026.1815244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 29.04.2026. Verfasst von Jun-Peng Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Immunotherapy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant chemotherapy combined with immunotherapy (NACI) is promising for treating locally advanced esophageal squamous cell carcinoma (LA-ESCC), yet a subset of patients exhibit a pathological non-response (pNR). The prognosis and risk factors for pNR to NACI remain unclear.

Methods

We retrospectively analyzed 253 patients with LA-ESCC who received NACI followed by surgery between 2020 and 2023. The immune checkpoint inhibitors (ICIs), which included pembrolizumab (200 mg), camrelizumab (200 mg), tislelizumab (200 mg), sintilimab (200 mg), nivolumab (200 mg), and toripalimab (200 mg), were administered intravenously once every three weeks. Patients with >50% residual viable tumor cells (Becker TRG3) were classified as having a pNR, while the others were classified as having a pathological response (pR). Survival and recurrence patterns were compared between the two groups. Risk factors associated with pNR and prognosis were identified.

Results

The pNR rate was 39.5% (100/253). Compared with the pR group, the pNR group had significantly worse 3-year overall survival (OS) (58.2% vs. 75.8%, P = 0.001) and disease-free survival (DFS) (46.1% vs. 65.5%, P = 0.001), with higher rates of locoregional (13.0% vs. 4.6%, P = 0.015) and distant recurrence (19.0% vs. 7.8%, P = 0.008). Multivariate analysis confirmed that pNR was an independent risk factor for poor OS (HR 1.926; 95% CI 1.250–2.970; P = 0.003) and DFS (HR 1.899; 95% CI 1.300–2.775; P = 0.001). Lymphovascular invasion (LVI) and perineural invasion (PNI) were independent risk factors for pNR (both P<0.001). Within the pNR subgroup, the PNI and ypN2/N3 stage were independent prognostic factors for poor survival (all P<0.05). Conclusion pNR to NACI strongly predicts worse outcomes in LA-ESCC patients. LVI and PNI are key risk factors, with PNI or advanced ypN stage further defining a high-risk pNR subgroup warranting aggressive postoperative management and surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmunotherapyImmune Checkpoint InhibitorsHumansFemaleMaleRisk FactorsRetrospective StudiesPrognosisMiddle AgedAgedNeoplasm Staging

Stichwörter der Autor:innen

esophageal squamous cell carcinomaneoadjuvant immunotherapypathological non-responseprognosisrisk factors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Fujian Key Laboratory of Translational Cancer Medicine, Fujian Cancer Hospital, Fuzhou, China.
  • Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fuzhou, China.
  • NHC Key Laboratory of Cancer and Metabolism, Fujian Cancer Hospital, Fuzhou, China.

Zitieren

APA

Lin, J. P., Lin, H., He, H., Zhuang, F. N., Chen, W. J., Chen, Y. J., Wang, P., Zhou, H., Wei, W. W., Gao, P. Q., Liu, S. Y., & Wang, F. (2026). Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1815244

Vancouver

Lin JP, Lin H, He H, Zhuang FN, Chen WJ, Chen YJ, et al. Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1815244

BibTeX
@article{Lin2026,
  author = {Lin, Jun-Peng and Lin, Hui and He, Hao and Zhuang, Feng-Nian and Chen, Wei-Jie and Chen, Yu-Jie and Wang, Peiyuan and Zhou, Hang and Wei, Wen-Wei and Gao, Peng-Qiang and Liu, Shuo-Yan and Wang, Feng},
  title = {Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1815244}
}
Kostenlos starten →